Dash Bio Secures $11M to Accelerate a New Era in Bioanalysis — Bringing Total Funding to $17.5M
Dash’s Fully Automated Bioanalysis Platform Is Reshaping Drug Development with Speed, Precision, and Scale NEWTON, Mass., July 23, 2025 /PRNewswire/ — Dash Bio, a preclinical and clinical bioanalysis company reinventing the speed and scalability of drug development, today…